Press Releases

FILTER BY

Drug Delivery Devices Offering Enhanced Connectivity to Find Higher Uptake Among Hospitals

Drug Delivery Devices Offering Enhanced Connectivity to Find Higher Uptake Among Hospitals

The rise of targeted therapy and drug compounds is prompting the development of novel drug delivery approaches such as nano gel and transdermal patches. Although intravenous (IV) infusion continues to dominate the market, subcutaneous, intradermal, and intramuscular modes will gain significant traction in five to eight years, when approximately 30 to 35 new products will be launched. Digital transformation will especially play a role in driving the $88.2 billion market in 2018 toward a $125 billion market by 2023, at a compound annual growth rate of approximately 7.2%.

MetGen Earns Acclaim from Frost & Sullivan for its Unique, Customized Enzyme Technologies, METNIN™ and ENZINE®

MetGen Earns Acclaim from Frost & Sullivan for its Unique, Customized Enzyme Technologies, METNIN™ and ENZINE®

Based on its recent analysis of the European industrial enzymes market, Frost & Sullivan recognizes Finland-based MetGen with the 2019 European Technology Innovation Award for its enzyme technologies, METNIN™ and ENZINE®. METNIN™ enables complete valorization of lignin for use in various applications, allowing the products made of lignin to be more sustainable and have a reduced carbon footprint. Unlike most competing solutions, it can also depolymerize and activate lignin under harsh conditions, such as alkaline pH (pH~11). Uniquely, it helps users tailor other properties such as solubility to water or solvents, polarity, and glass transition temperature.

Frost & Sullivan Lauds The Qt Company for Developing a Low-cost Unified UI/UX Software Platform for the Automotive Industry

Frost & Sullivan Lauds The Qt Company for Developing a Low-cost Unified UI/UX Software Platform for the Automotive Industry

Based on its recent analysis of the global automotive User Interface/User Experience (UI/UX) market, Frost & Sullivan recognizes The Qt Company with the 2019 Global Customer Value Leadership Award. Responding to the rising demand for UIs, performance, and intelligence in next-generation automobile models, The Qt Company rolled out a series of high-performance software solutions including Qt Automotive Suite, Qt Safe Renderer, Qt Design Studio, and the Qt for Python. Its collaboration model with industry players, coupled with customer engagement, has allowed it to focus on continuous development, provide superior products with quality performance and ultimately, present unrivaled customer value.

Medisanté Earns Acclaim from Frost & Sullivan for Ensuring Better Care Outcomes while Reducing Costs

Medisanté Earns Acclaim from Frost & Sullivan for Ensuring Better Care Outcomes while Reducing Costs

Based on its recent analysis of the global remote patient monitoring (RPM) market, Frost & Sullivan recognizes Medisanté with the 2019 Global Enabling Technology Leadership Award for integrating patient-generated health data (PGHD) direct-to-cloud into any existing clinical system. Medisanté’s powerful partnership strategy is key to its success in streamlining RPM initiatives anywhere in the world. By combining advanced technology from Vodafone (for cellular IoT technology), Amazon Web Services (for cloud infrastructure), and Gemalto (for chip cards and enterprise-grade security), Medisanté makes RPM more accessible to care teams and patients. It also involves biomedical engineers to facilitate secure and cost-effective scaling.

MabPlex Lauded by Frost & Sullivan for Global Expansion of ADC Contract Manufacturing Services

MabPlex Lauded by Frost & Sullivan for Global Expansion of ADC Contract Manufacturing Services

Based on its recent analysis of the global antibody drug conjugate (ADC) contract manufacturing services market, Frost & Sullivan recognizes China-based MabPlex International, Ltd (MabPlex) with the 2019 Global Growth Excellence Leadership Award. MabPlex emerges as one of the few large-scale, end-to-end ADC producers, providing services from early-stage development to commercialization. The company’s proprietary conjugation platform and innovative technologies deliver novel and clinically effective ADCs for cancer therapeutics around the world.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.